company-logo

Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.

Theranexus Dividend Announcement

Theranexus does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on Theranexus dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Theranexus Dividend History

Theranexus Dividend Yield

Theranexus current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Theranexus stock? Use our calculator to estimate your expected dividend yield:

Theranexus Financial Ratios

P/E ratio-1.26
PEG ratio-0.24
P/B ratio-1129.30
ROE707.92%
Payout ratio0.00%
Current ratio1.21
Quick ratio1.21
Cash Ratio0.17

Theranexus Dividend FAQ

Does Theranexus stock pay dividends?
Theranexus does not currently pay dividends to its shareholders.
Has Theranexus ever paid a dividend?
No, Theranexus has no a history of paying dividends to its shareholders. Theranexus is not known for its dividend payments.
Why doesn't Theranexus pay dividends?
There are several potential reasons why Theranexus would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Theranexus ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Theranexus has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Theranexus a dividend aristocrat?
Theranexus is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Theranexus a dividend king?
Theranexus is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Theranexus a dividend stock?
No, Theranexus is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Theranexus stocks?
To buy Theranexus you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Theranexus stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.